Refractory Germ-cell clinical trials at UC Cancer
1 research study open to eligible people

• Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

  open to eligible people ages 18 years and up

  This research study is studying a combination of drugs as a possible treatment for rare genitourinary malignancies. -The names of the study drugs involved in this study are: - Nivolumab - Ipilimumab

  at UCSD

Last updated: March 1, 2019